Leeward Investments LLC MA Reduces Holdings in Integra LifeSciences Holdings Corporation $IART

Leeward Investments LLC MA decreased its position in shares of Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 3.6% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 374,809 shares of the life sciences company’s stock after selling 13,939 shares during the period. Leeward Investments LLC MA owned about 0.48% of Integra LifeSciences worth $4,599,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in IART. Wealth Enhancement Advisory Services LLC acquired a new position in Integra LifeSciences during the 1st quarter worth $251,000. Teacher Retirement System of Texas acquired a new position in Integra LifeSciences during the 1st quarter worth $223,000. Principal Financial Group Inc. grew its holdings in Integra LifeSciences by 2.5% during the 1st quarter. Principal Financial Group Inc. now owns 433,924 shares of the life sciences company’s stock worth $9,542,000 after acquiring an additional 10,492 shares in the last quarter. Envestnet Asset Management Inc. grew its holdings in Integra LifeSciences by 4.6% during the 1st quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company’s stock worth $605,000 after acquiring an additional 1,204 shares in the last quarter. Finally, Arizona State Retirement System grew its holdings in Integra LifeSciences by 4.2% during the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company’s stock worth $437,000 after acquiring an additional 795 shares in the last quarter. 84.78% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have weighed in on the stock. Truist Financial set a $15.00 price objective on shares of Integra LifeSciences and gave the stock a “hold” rating in a report on Wednesday, October 15th. Citigroup reaffirmed a “sell” rating and issued a $12.00 price target (up from $10.00) on shares of Integra LifeSciences in a report on Tuesday, October 7th. Finally, Weiss Ratings reaffirmed a “sell (d)” rating on shares of Integra LifeSciences in a report on Saturday. Two equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and four have issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus target price of $16.17.

Integra LifeSciences Trading Up 1.5%

NASDAQ IART opened at $16.12 on Monday. The firm has a market capitalization of $1.26 billion, a PE ratio of -2.47 and a beta of 1.21. The company has a 50-day simple moving average of $14.72 and a 200-day simple moving average of $13.92. Integra LifeSciences Holdings Corporation has a one year low of $11.06 and a one year high of $27.13. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.73 and a current ratio of 1.23.

Integra LifeSciences (NASDAQ:IART) last issued its quarterly earnings data on Thursday, July 31st. The life sciences company reported $0.45 earnings per share for the quarter, beating the consensus estimate of $0.43 by $0.02. The firm had revenue of $415.61 million for the quarter, compared to the consensus estimate of $395.06 million. Integra LifeSciences had a negative net margin of 30.87% and a positive return on equity of 12.15%. Integra LifeSciences’s quarterly revenue was down .6% compared to the same quarter last year. During the same period last year, the firm posted $0.63 EPS. Integra LifeSciences has set its FY 2025 guidance at 2.190-2.290 EPS. Q3 2025 guidance at 0.400-0.450 EPS. On average, equities analysts forecast that Integra LifeSciences Holdings Corporation will post 2.45 earnings per share for the current year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.